The APEX study presents the results of 2 dosing regimens of guselkumab (Q4W and Q8W) in biologic-naïve patients with psoriatic arthritis (PsA).
Dermatology Education Foundation DERM NP/PA CME Conference
Advertisement
Advertisement
The APEX study presents the results of 2 dosing regimens of guselkumab (Q4W and Q8W) in biologic-naïve patients with psoriatic arthritis (PsA).